



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Kang, MJY;Eratne, D;Dean, O;Berk, M;Walker, AJ;Wannan, C;Malpas, CB;Cicognola, C;Janelidze, S;Hansson, O;Grewal, J;Mitchell, PB;Hopwood, M;Pantelis, C;Santillo, AF;Velakoulis, D

Title:

Plasma Glial Fibrillary Acidic Protein and Neurofilament Light Are Elevated in Bipolar Depression: Evidence for Neuroprogression and Astrogliosis

Date:

2025-08-01

Citation:

Kang, M. J. Y., Eratne, D., Dean, O., Berk, M., Walker, A. J., Wannan, C., Malpas, C. B., Cicognola, C., Janelidze, S., Hansson, O., Grewal, J., Mitchell, P. B., Hopwood, M., Pantelis, C., Santillo, A. F. & Velakoulis, D. (2025). Plasma Glial Fibrillary Acidic Protein and Neurofilament Light Are Elevated in Bipolar Depression: Evidence for Neuroprogression and Astrogliosis. *Bipolar Disorders*, 27 (5), pp.379-388. <https://doi.org/10.1111/bdi.70029>.

Persistent Link:












<https://hdl.handle.net/11343/362485>

License:

CC BY

ORIGINAL ARTICLE OPEN ACCESS

Plasma Glial Fibrillary Acidic Protein and Neurofilament Light Are Elevated in Bipolar Depression: Evidence for Neuroprogression and Astrogliosis

Matthew J. Y. Kang^{1,2}  | Dhamidhu Eratne^{1,2}  | Olivia Dean^{3,4}  | Michael Berk³  | Adam J. Walker³  | Cassandra Wannan^{5,6}  | Charles B. Malpas^{7,8} | Claudia Cicognola^{9,10} | Shorena Janelidze⁹ | Oskar Hansson^{9,10} | Jasleen Grewal¹¹ | Philip B. Mitchell¹²  | Malcolm Hopwood^{2,13}  | Christos Pantelis^{2,14,15}  | Alexander F. Santillo^{9,10}  | Dennis Velakoulis^{1,2} 

¹Neuropsychiatry Centre, The Royal Melbourne Hospital, Melbourne, Victoria, Australia | ²Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia | ³Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Deakin University and Barwon Health, Geelong, Victoria, Australia | ⁴Florey Institute for Neuroscience and Mental Health, Parkville, Victoria, Australia | ⁵Orygen, Parkville, Victoria, Australia | ⁶Centre for Youth Mental Health, The University of Melbourne, Parkville, Victoria, Australia | ⁷Melbourne School of Psychological Sciences, The University of Melbourne, Melbourne, Victoria, Australia | ⁸Department of Medicine, The Royal Melbourne Hospital, Melbourne, Victoria, Australia | ⁹Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden | ¹⁰Memory Clinic, Skåne University Hospital, Malmö, Sweden | ¹¹Alfred Mental and Addiction Health, Alfred Health, Melbourne, Victoria, Australia | ¹²Discipline of Psychiatry and Mental Health, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia | ¹³Professorial Psychiatry Unit, Ramsay Clinic Albert Road, Melbourne, Victoria, Australia | ¹⁴Western Centre for Health Research & Education, University of Melbourne & Western Health, Sunshine Hospital, St Albans, Victoria, Australia | ¹⁵Monash Institute of Pharmaceutical Sciences (MIPS), Monash University, Melbourne, Victoria, Australia

Correspondence: Matthew J. Y. Kang (matthew.kang1@unimelb.edu.au)

Received: 21 March 2025 | **Revised:** 23 March 2025 | **Accepted:** 24 March 2025

Funding: This study was supported by: MACH MRFF RART 2.2, NHMRC (1185180), and Psychiatry and Rehabilitation Division, Region Skåne, Sweden. The role of these funding sources was to support research study staff and biosample analyses. The healthy controls cohort was part of a major Australian Department of Industry Co-operative Research Centre (CRC) grant—<https://researchdata.andis.org.au/treatment-resistant-schizophrenia-biobank/1325206>. M.K. is supported by the Nick Christopher PhD scholarship and the Research Training Program Scholarship from the Department of Psychiatry, University of Melbourne with contributions from the Australian Commonwealth Government, and the Ramsay Hospital Research Foundation. A.F.S. is supported by the Swedish federal government under the ALF agreement. M.B. is supported by a NHMRC Leadership 3 Investigator grant (GNT2017131). C.P. was supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (1105825), an NHMRC L3 Investigator Grant (1196508). P.B.M. is supported by an NHMRC Investigator Grant (1177991). In the last three years, he has received remuneration from Janssen (Australia) for lectures and advisory board membership. O.H.'s work at Lund University was supported by Alzheimer's Association (ZEN24-1069572, SG-23-1061717), GHR Foundation, Swedish Research Council (2022-00775), ERA PerMed (ERAPERMED2021-184), Knut and Alice Wallenberg foundation (2022-0231), Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, Swedish Alzheimer Foundation (AF-980907), Swedish Brain Foundation (FO2021-0293), Parkinson foundation of Sweden (1412/22), Cure Alzheimer's fund, Rönström Family Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Skåne University Hospital Foundation (2020-O000028), Regionalt Forskningsstöd (2022-1259) and Swedish federal government under the ALF agreement (2022-Projekt0080). A.J.W. was previously supported by a Trisno Family Research Fellowship. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Keywords: biological markers | bipolar disorder | depression | glial fibrillary acidic protein | mania | mental health | neurofilament light chain | psychiatry

ABSTRACT

Background: Recent advances now allow detection of brain-specific proteins in blood, including neurofilament light chain (NfL), a marker of axonal pathology, and glial fibrillary acidic protein (GFAP), indicative of astrocytic activation. Given the evidence of astroglial pathology and neuronal dysfunction in bipolar disorder, and ongoing debates on neuroprogression, we investigated plasma NfL and GFAP levels in affected individuals.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2025 The Author(s). *Bipolar Disorders* published by John Wiley & Sons Ltd.

Methods: This study analysed plasma NfL and GFAP measured in 216 individuals using Simoa. We used bootstrapped general linear models (GLM) to compare plasma NfL and GFAP levels between people with bipolar depression ($n = 120$) and healthy controls ($n = 96$), adjusting for age, sex, and weight. We examined associations between these biomarkers and clinical variables while adjusting for multiple comparisons. For sensitivity analyses, predictors were evaluated using Bayesian model averaging (BMA).

Results: Plasma GFAP ($\beta = 0.21$ [0.07, 0.35], $p = 0.006$) and NfL ($\beta = 0.06$ [0.01, 0.10], $p = 0.028$) were elevated in people with bipolar depression. Illness duration was positively associated with NfL ($r = 2.97$, $p = 0.002$), and further supported by BMA analysis (posterior inclusion probability, PIP = 0.85). Age of onset was positively associated with GFAP ($r = 0.246$, $p = 0.041$), which was also supported by BMA analysis (PIP = 0.67).

Conclusions: These findings indicate increased plasma NfL and GFAP levels in bipolar disorder. Our findings support the neuroprogression hypothesis, where prolonged illness duration contributes to neuroaxonal damage. Elevated GFAP in those with later onset suggests a role for neuroinflammation, potentially linked to increased cardiovascular and metabolic comorbidities.

1 | Introduction

Bipolar disorder is a chronic psychiatric condition characterised by recurrent depressive and manic episodes, often accompanied by impairments in cognition and daily functioning that may persist even during remission. The observed association between bipolar disorder and long-term cognitive impairment has led to the “neuroprogression” hypothesis [1, 2], which suggests that elevated levels of inflammation resulting from repeated mood episodes drive neuropathological processes that manifest as progressive cognitive decline, treatment resistance and structural brain changes [1, 3, 4]. However, the supporting research is mixed. For instance, an umbrella review by Carvalho et al. highlighted that much of the literature linking inflammation and bipolar disorder are limited by bias, fueling ongoing debates in the field [5, 6].

Blood-based biomarker research investigating the pathophysiology of bipolar disorder has focused on systemic markers such as cytokines, which are not brain-specific [7]. Recent technological advancements have made it possible to accurately measure picograms of brain-derived proteins in the blood [8]. Two markers have drawn attention in the neurodegenerative disease space. Neurofilament light chain (NfL) is a cytoskeletal intermediate filament protein expressed in neurons, with elevated concentrations in blood following neuronal injury and degeneration [9, 10]. Glial fibrillary acidic protein (GFAP) is a component of the astrocyte cytoskeleton, with elevated concentrations being associated with astrocyte activation, a marker of neuroinflammation [11]. These proteins are of particular interest in bipolar disorder, given that the condition has been linked with neuronal dysfunction and neuroinflammation [3]. By examining these brain-specific biomarkers, we can gain valuable insights into the neurobiological mechanisms underlying bipolar disorder.

Our recent systematic review [12] found that there was mixed and limited literature as to whether NfL levels are elevated in bipolar disorder compared to healthy controls. The mood states of these cohorts at the time of blood sampling were varied (euthymic, depressed, or mixed). Two studies specifically explored bipolar depression and found that plasma NfL was mildly elevated compared to healthy controls [13, 14]. Only one study investigated GFAP in a small number of people with bipolar disorder found that serum GFAP levels were similar to healthy controls [11]. None of these studies examined the correlation between plasma NfL/GFAP and clinical variables such as symptom severity.

Investigating NfL and GFAP in the blood of individuals with bipolar depression could provide valuable insights into the extent of neuronal pathology and astrocyte activation associated with the disorder, providing new avenues for therapeutic strategies. In this study, we aimed to further investigate the bipolar depression group by analysing plasma GFAP concentrations and comparing them with healthy controls. Furthermore, we aimed to build on our previous finding that NfL was higher in people with bipolar disorder [14], by exploring the relationships between NfL and GFAP with clinical and demographic factors in bipolar disorder to better understand what illness-related factors are associated with higher biomarker levels.

2 | Methods

2.1 | Study Cohorts

This study, which is part of The Markers in Neuropsychiatric Disorders Study (The MiND Study, <https://themindstudy.org>), followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines [15], and included 210 individuals from two multicentre cohorts. The bipolar depression cohort were from a registered clinical trial (ACTRN12612000830897), of adjunctive mitochondrial agents and N-acetylcysteine [16]. Participants were at least 18 years old, met DSM-IV-TR diagnostic criteria for bipolar disorder, experiencing a bipolar depressive episode of at least moderate severity at the time of the study blood collection, and recruited from both inpatient and outpatient psychiatric services in Australia between 2013 and 2015. Participants were required to remain on stable treatment for at least 1 month prior to the study.

The healthy controls were pooled from the Cooperative Research Centre (CRC) for Mental Health Study [17], had no current or past psychiatric or neurological illness, and recruited from the general community in Australia between 2012 and 2018. We have reported plasma NfL values for this cohort previously [18].

2.2 | Ethics

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with

the Helsinki Declaration of 1975, as revised in 2013. All procedures involving human subjects/patients were approved by the relevant Human Research Ethics Committees and all participants provided written informed consent prior to participation. This study was approved by the Melbourne Health Human Research Ethics Committee (MH HREC 2020.142).

2.3 | Sample Analysis

The samples from both cohorts [16, 17] were collected at fasting state in plasma EDTA tubes, and stored at -80°C . Samples were randomised before analysis, and analyses were blinded to diagnosis. All plasma NfL levels were measured on the Quanterix SR-X analyser using the same version of the Simoa NF-Light kits. All plasma GFAP levels were measured using the same version of the Simoa GFAP Discovery kits. Both NfL and GFAP are suitable for retrospective analysis, as it is robust to multiple freeze–thaw cycles and time [19–21]. All analyses were completed in the same batch.

2.4 | Statistical Analysis

All statistical analyses were performed using *R* (Version 4.2.2) Jamovi (Version 2.6.22.0) and GAMLj package (Version 3.4.2) [22–24]. To compare the demographic variables between bipolar depression and healthy controls, we used Mann–Whitney *U*-tests and Pearson's chi-square tests of independence.

General linear models (GLM) were used to compare NfL and GFAP levels between healthy controls and individuals with bipolar disorder. NfL and GFAP values were entered as dependent variables and were \log_{10} transformed due to positively skewed distributions, and we reported raw values for easier interpretation. Cohort group, age, sex and weight were entered as independent variables, and 95% confidence intervals were computed (nonparametric bootstrapping, 1000 replicates), with statistical significance defined as any confidence interval not including the null (at 95% level).

2.4.1 | Exploratory Analysis of Clinicodemographic Variables and Biomarker Values

2.4.1.1 | Conventional Frequentist Analysis. For exploratory analysis of clinical and demographic factors that may explain the elevated biomarker level in bipolar disorder, we used Spearman's rho for continuous variables and Welch's *t*-test for categorical variables to analyse their associations. We adjusted for multiple comparisons using Benjamini–Hochberg false discovery rate (FDR) correction. All statistical assumptions were checked, including multicollinearity in linear models using the variance inflation factor (VIF).

2.4.1.2 | Bayesian Model Averaging. To further mitigate the problem of using multiple predictors, we used Bayesian model averaging (BMA) a validated statistical technique that allows for all potential predictors to be examined in the model in parallel, while simultaneously considering all possible formulations of the model [25]. The overall statistical solution is composed of all possible combinations of predictors weighted

by model fit. As the best-fitting combinations contribute more to the final model, and the worst-fitting models contribute less, this naturally deals with the problem of model selection without having to impose model selection bias.

Briefly, for *p* predictors, BMA estimates all possible models corresponding to the 2^p possible combinations of predictors. The fit of each model was then evaluated using the log of the posterior odds. Parameter estimates were averaged over all models, weighted for the fit of each model, which inherently adjusted for the uncertainty associated with model selection bias.

The importance of each predictor was evaluated by the posterior inclusion probability (PIP) value, which was the probability that the parameter is not zero given the data. Predictors with PIP values > 0.5 were considered 'important'. Predictions of NfL or GFAP for each patient were computed using the posterior predictive distribution averaged across all models. BMA was performed using the Bayesian adaptive sampling package [26]. As one variable (number of depressive episodes) had 11 missing values, all BMA analyses were run with and without this variable to ensure that the results were consistent.

3 | Results

3.1 | Study Cohort Characteristics

A total of 216 participants had adequate plasma samples available for NfL and GFAP analyses. The 120 participants with bipolar disorder comprised of 75 (62%) females and 45 (38%) males, with a mean \pm SD age of 43.9 ± 12.0 years and weight of 84.3 ± 21.0 kg. For healthy controls ($n = 96$), there were 50 (52%) females and 46 (48%) males, with a mean \pm SD age of 44.7 ± 14.4 years and weight of 77.3 ± 15.4 kg. The bipolar depression cohort and the healthy controls were not statistically different in terms of their demographic measures, including their weight (Table 1).

As for the clinical characteristics of the bipolar depression cohort, their mean age at diagnosis by a health clinician was

TABLE 1 | Descriptive comparison of the cohorts.

	Bipolar depression (<i>n</i> = 120)	Controls (<i>n</i> = 96)
Gender		
Female	75 (62%)	50 (52%)
Male	45 (38%)	46 (48%)
Age (years)	43.9 (12.0)	44.7 (14.4)
Weight (kg)	84.3 (21.0)	77.3 (15.4) [<i>n</i> = 87]
Height (cm)	170.3 (9.1) [<i>n</i> = 119]	170.3 (10.8) [<i>n</i> = 89]
NfL (pg/mL)	8.7 (12.8)	9.4 (14.2)
GFAP (pg/mL)	95.55 (49.31)	75.47 (46.94)

Note: Values expressed as mean (SD); *n* (%).
Abbreviations: GFAP = glial fibrillary acidic protein; NfL = Neurofilament light chain.

34 ± 11 years old, duration of bipolar illness (from age of self-reported onset of symptoms) was 23 ± 11 years, 78 (65%) individuals were prescribed at least one mood stabiliser, and 75 (69%) individuals reported having experienced 20+ depressive episodes in their lifetime. With regards to their symptom severity and functioning, their mean MADRS was 29.2 ± 5.2, BDRS was 25.7 ± 6.6, HAM-A was 17.6 ± 5.7, YMRS was 3.9 ± 3.4, Q-LES-Q was 40.1 ± 12.7 and CGI-S was 4.7 ± 0.8.

3.2 | Biomarker Levels in Bipolar Depression and Healthy Controls

The raw mean ± SD of plasma NfL was 8.7 ± 12.8 pg/mL in bipolar depression and 9.4 ± 14.2 pg/mL in healthy controls.

The raw mean ± SD of GFAP was 95.6 ± 49.3 pg/mL in bipolar depression and 75.5 ± 46.9 pg/mL in healthy controls. Plasma GFAP was significantly elevated in people with bipolar depression compared to healthy controls after adjusting for age, sex and weight ($\beta = 0.21$ [0.07, 0.35], $p = 0.006$). Consistent with our previous finding [14], log-transformed NfL was also significantly elevated in people with bipolar depression compared to healthy controls ($\beta = 0.06$ [0.01, 0.10], $p = 0.028$; Figure S1).

3.3 | Clinical Correlates of NfL and GFAP

Age positively correlated with both NfL and GFAP (Table 2). People who had a history of substance use disorder (SUD) in their lifetime had significantly lower GFAP concentration than

TABLE 2 | Clinical correlates of NfL and GFAP in bipolar depression.

Characteristic	N = 120, mean (SD); n (%)	NfL correlation (p-value)	GFAP correlation (p-value)
Age (years)	43.89 (11.95)	0.468 (p < 0.001)	0.34 (p = 0.002)
Gender	Females: 75 (63%) Male: 45 (37%)	0.281 (p = 0.822)	0.13 (p = 0.362)
Weight (kg)	84.3 (21.0)	-0.162 (p = 0.196)	-0.113 (p = 0.389)
History of substance dependence	37 (31%)	2.265 (p = 0.097)	2.970 (p = 0.029)
Duration of Illness (n = 117)	23 (11)	0.331 (p = 0.002)	0.15 (p = 0.271)
Age at diagnosis (n = 119)	34 (11)	0.253 (p = 0.026)	0.246 (p = 0.040)
Mood stabiliser	78 (65%)	-1.417 (p = 0.336)	-2.117 (p = 0.141)
Lithium	18 (18%)	0.386 (p = 0.822)	-0.647 (p = 0.729)
Antipsychotic	72 (60%)	1.034 (p = 0.527)	0.116 (p = 0.908)
No. of depressive episodes (n = 109)		0.185 (p = 0.173)	0.127 (p = 0.33)
1-10	15 (14%)		
11-20	19 (17%)		
20+	75 (69%)		
MADRS	29.2 (5.2)	-0.03 (p = 0.822)	0.114 (p = 0.389)
BDRS	25.7 (6.6)	-0.073 (p = 0.580)	0.023 (p = 0.908)
HAM-A	17.6 (5.7)	-0.084 (p = 0.572)	-0.012 (p = 0.908)
YMRS	3.9 (3.4)	-0.078 (p = 0.580)	-0.158 (p = 0.271)
Q-LES-Q	40.1 (12.7)	0.14 (p = 0.301)	0.083 (p = 0.566)
CGI-S	4.7 (0.8)	0.041 (p = 0.822)	0.149 (p = 0.271)
IL-6	1.90 (1.53)	0.099 (p = 0.527)	-0.031 (p = 0.892)
TAC (n = 119)	0.47 (0.11)	-0.005 (p = 0.958)	0.102 (p = 0.447)
GFAP	95.55 (49.31)	0.455 (p < 0.001)	N/A
NfL	8.68 (12.76)	N/A	0.455 (p < 0.001)

Note: p-values corrected for multiple comparisons; correlation with Spearman's rho for continuous variables and Welch's t-test for categorical variables; bolded indicating $p < 0.05$.

Abbreviations: BDRS = Bipolar Depression Rating Scale; CGI-S = Clinical Global Impressions—Severity Scale; GFAP = glial fibrillary acidic protein; HAM-A = Hamilton Anxiety Rating Scale; IL-6 = Interleukin-6; MADRS = Montgomery-Åsberg Depression Rating Scale; NfL = Neurofilament light chain; Q-LES-Q = Quality of Life Enjoyment and Satisfaction Questionnaire; TAC = Total Antioxidant Capacity; YMRS = Young Mania Rating Scale.

those without ($t=2.97$, $df=95.75$, adjusted $p=0.024$). However, people with a SUD history were younger than those without (mean 38.2 ± 8.6 years vs. 46.4 ± 12.4 years; $F=13.63$, $p < 0.001$). The multivariable GLM including age and SUD history found that SUD was not significantly associated with GFAP ($\beta = -0.33$; $[-0.68, 0.02]$; $p=0.058$), suggesting therefore, that the difference was attributable to age.

Both longer duration of illness and older age at diagnosis were positively correlated with higher NfL concentration (Figure 1). Older age at diagnosis positively correlated with higher GFAP concentration (Figure 2). Duration of illness (VIF=1.69) and age at diagnosis (VIF=2.08) were not significant for multicollinearity (VIF < 3.0). Neither duration of illness nor age at diagnosis were significant in the GLMs when they were added with age to predict NfL or GFAP.

3.4 | BMA Analysis

3.4.1 | Plasma NfL

BMA revealed several important predictors of NfL. The posterior inclusion probabilities (PIP) are shown in Table 3. The strongest evidence was observed for GFAP (PIP=1), whilst duration of illness was also strongly supported (PIP=0.85). The remaining predictors (Table 3), including age, had PIPs < 0.5, and only GFAP was a significant independent predictor of NfL, with its 95% CI not capturing zero. Taken in the context of the PIP value > 0.5, this indicates that GFAP is important to include in any well-fitting model predicting NfL using the possible variables, whilst there is some doubt about the magnitude of the other predictors in predicting NfL. A visual

representation of the importance of each predictor in the top 20 models is shown in Figure 3, and the predictors ranked by their PIP in Figure S2.

3.4.2 | Plasma GFAP

NfL (PIP=1) was considered an important predictor (Figure 3; Table 3), whilst age at diagnosis was a moderately strong predictor (PIP=0.67) but its estimate was less precise and included 0 in its 95% CI ($B=0.78$, 95% CI: 0–1.74), which taken together implies that this predictor is important to include in any well-fitting model, but there is considerable uncertainty regarding the specific magnitude of this relationship. The other variables, including age, were not considered to be strong predictors of GFAP. A visual representation of the importance of each predictor in the top 20 models is shown in Figure 4, and the predictors ranked by their PIP in Figure S3.

4 | Discussion

This is the largest study to date exploring the relationship between brain-specific markers of neurodegeneration and astroglial dysfunction in people with bipolar depression. By extending on our previous work [14], we found that both plasma NfL and GFAP are elevated in people with bipolar depression compared to healthy controls. Plasma NfL was associated with a longer duration of illness and may represent a marker of illness stage. Our novel finding that plasma GFAP was elevated in bipolar depression suggests that there is increased activation of astrocytes, which has been linked with neuroinflammation, adding to the debated literature about the role of




FIGURE 1 | Scatterplot of plasma NfL and duration of illness.




FIGURE 2 | Scatterplot of plasma GFAP and age at diagnosis.

inflammation in bipolar disorder [27–29] and the neuroprogression hypothesis [5, 6]. Plasma GFAP was also positively associated with a later age of bipolar diagnosis, which suggests that those with a later age of onset have a distinct neurobiological process. These proteins could serve as objective biomarkers that identify homogenous phenotypes in bipolar disorder, and address the problems of heterogeneity which hinder research efforts [30].

The difference in NfL concentrations between people with bipolar disorder and unaffected individuals was small and only evident after adjusting for known covariates. This contrasts with the markedly elevated concentrations (at least two-fold) seen in neurodegenerative disorders such as dementia and multiple sclerosis [31, 32], suggesting that the subtle increase in bipolar disorder may be due to a different or less intense process. Aggio et al.'s study [13] similarly found that NfL was mildly elevated in people with bipolar depression ($n=45$) and linked this to neuronal distress with axonal damage due to an ageing-related process, or “accelerated brain ageing.” Accelerated brain ageing refers to the age gap between chronological and the estimated neuroanatomical age, which has been observed in various psychiatric disorders including bipolar disorder [33, 34]. Plasma NfL has been proposed as a potential marker of brain ageing [35, 36] due to its age-related increases [37]. As the brain atrophies with age [38], NfL is released from dendrites and axons into CSF and blood [39]. The subtle elevation of NfL levels in bipolar disorder after adjustment for chronological age supports the notion that there is accelerated ageing in bipolar disorder, adding to the current debate in the literature [33, 34, 40].

Moreover, our finding that plasma NfL levels correlate with the duration of bipolar disorder may be evidence of the progressive

burden of the condition on the brain. This supports the “neuroprogression” hypothesis, which postulates that a subset of people have a progressive trajectory due to pathological rewiring and degeneration of the brain over the course of the illness [1, 41, 42]. Longitudinal neuroimaging studies have found that people with bipolar disorder have faster cortical atrophy [43] and ventricular enlargement [44] beyond what is expected with normal ageing [45]. Similarly, our BMA analysis also identified that duration of illness, and not chronological age, was better predictive of plasma NfL levels. This negative finding of chronological age not predicting plasma NfL was surprising given it is contrary to well-established literature [37], including our own conventional frequentist analysis in this study. Considering the broader literature, our finding suggests that the “neuroprogressive” pathology of bipolar disorder outpaces chronological age-related brain changes, and this has a neuroinflammatory component given the elevated GFAP levels. In clinical practice, NfL may have utility in identifying and monitoring individuals with bipolar disorder vulnerable to neuroprogression, similar to how it has been proposed as a biomarker of cognition and prognosis in neurological conditions including Parkinson's disease [46] and mild cognitive impairment [47].

This novel finding that the duration of bipolar disorder is a better predictor of NfL than chronological age highlights the strength of BMA analysis in being able to consider a broad range of possible predictors, examine a wide range of models based on all the variables available, and provide a value that represents the importance of each predictor across all possible models. This contrasts with the traditional frequentist approach, which can only consider one model at a time introducing bias [48]. Given that plasma NfL level is impacted by

TABLE 3 | BMA analysis for prediction of plasma NFL and GFAP concentrations.

Predictor	NFL		GFAP	
	B [95% CI]	PIP	B [95% CI]	PIP
Age	0.13 [0–1.22]	0.26	0.13 [0–1.22]	0.16
Sex	0.51 [–0.51–6.27]	0.11	0.51 [–0.51–6.27]	0.06
Weight	0 [0–0]	0.47	0 [0–0]	0.04
Substance dependence history	–0.93 [–11.03–0.1]	0.07	–0.93 [–11.03–0.1]	0.08
Duration of illness	–0.05 [–0.58–0]	0.85	–0.05 [–0.58–0]	0.08
Age at diagnosis	0.78 [0–1.74]	0.09	0.78 [0–1.74]	0.67
Mood stabiliser	1.67 [–0.02–17.29]	0.07	1.67 [–0.02–17.29]	0.13
Lithium	0.32 [0–0]	0.10	0.32 [0–0]	0.05
Antipsychotic	0.32 [–0.39–2.65]	0.15	0.32 [–0.39–2.65]	0.05
MADRS	0.04 [0–0.58]	0.09	0.04 [0–0.58]	0.07
BDRS	0 [–0.07–0]	0.09	0 [–0.07–0]	0.05
HAM-A	0.1 [0–1.22]	0.32	0.1 [0–1.22]	0.10
YMRS	–0.23 [–2.44–0]	0.07	–0.23 [–2.44–0]	0.11
Q-LES-Q	0 [0–0]	0.11	0 [0–0]	0.04
CGI-S	1.29 [0–11.92]	0.15	1.29 [0–11.92]	0.14
IL-6	–0.14 [–1.57–0]	0.26	–0.14 [–1.57–0]	0.07
TAC	5.86 [0–65.95]	0.07	5.86 [0–65.95]	0.11
GFAP	4.14 [2.24–6.05]	1.00	N/A	N/A
NfL	N/A	N/A	4.14 [2.24–6.05]	1.00

Abbreviations: 95% CI = 95% credible intervals; B = model coefficients computed as the mean of the posterior distribution; PIP = posterior inclusion probability; SE = standard deviation of the posterior distributions.

many factors [8, 18], not limited to the person's age, weight, and physical health, the ability of BMA to consider a wide range of predictors uncovered an interesting insight in this study. Nonetheless, the limited age range of our cohort warrants further research incorporating younger and older cohorts with bipolar disorder. In addition, studies investigating the three-way relationship between NfL, neuroimaging, and the burden of bipolar disorder (longer duration, number of manic and/or depressive episodes) is required to validate this hypothesis that

the duration of bipolar illness has a greater burden on the brain age than chronological age.

Our finding of elevated GFAP levels in bipolar disorder suggests that neuroinflammation may be a component of this condition, especially in those with later onset of illness. This may be connected to the increased prevalence of cardiovascular and metabolic conditions in older adults, which are known to cause neuroinflammatory changes and oxidative stress in the brain [49]. Although we did not collect details about their cardiovascular health, the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE), which had a comparable cohort age (38.9 ± 12.1 years), found that individuals with a later age onset of bipolar disorder were more likely to have underlying medical comorbidities [50]. Combining this with our finding that GFAP was higher in those with later age of onset, this may represent an increased expression and release of GFAP from astrocytic activation as a form of defence response to neuroinflammation. However, GFAP did not correlate with peripheral interleukin-6 (IL-6) or total antioxidant capacity (TAC), suggesting that peripheral and CNS inflammation may contribute to the pathophysiology of bipolar disorder in distinct ways. Future studies should characterise cardiovascular and metabolic risk and compare this with biomarker levels.

It remains unclear whether mild increases in plasma NfL and/or GFAP in bipolar disorder are related to the trait (bipolar disorder) or state (depression, mania or mixed state) [10, 51]. Previous research by Steinacker et al. found that GFAP correlated with the severity of unipolar depressed state as measured by the MADRS [11]. We found that the severity of depressive symptoms did not correlate with plasma NfL nor GFAP suggests that unipolar and bipolar depression may have different underlying neurobiological processes. Despite lithium's postulated neuroprotective role [52], it also did not have a significant effect on plasma NfL nor GFAP, though it may have been underpowered considering that plasma NfL and GFAP levels were only mildly elevated in people with bipolar disorder. Furthermore, antipsychotic medication has been associated with elevated CSF NfL levels [53], but our study did not replicate this finding in plasma NfL.

This study has several limitations. The cross-sectional nature of the study makes it difficult to make causal inferences, so future studies with serial samples and longitudinal clinical data are needed. We lacked other important clinical information about the people with bipolar disorder, including renal function, previous medications, cognition and number of manic episodes. Investigating these biomarkers in manic states may yield important insights, although recruiting participants in acute mania is challenging. Furthermore, detailed history including the type and quantity of substance use would have been useful to better understand the correlation between substance use disorder history and NfL/GFAP, especially given the emerging evidence that chronic cocaine use and alcoholism are associated with elevated NfL levels [54, 55], highlighting a potential area for future research. Additional research involving cohorts in different phases of bipolar disorder (i.e., index episode, acute manic episode) is needed to validate whether the differences in NfL and GFAP are generalisable to the disorder or are episode dependent. Finally, we recommend




FIGURE 3 | Visualisation of the model space from the BMA analysis of NfL correlates. BDRS = Bipolar Depression Rating Scale; CGI-S = Clinical Global Impressions—Severity Scale; GFAP = glial fibrillary acidic protein; HAM-A = Hamilton Anxiety Rating Scale; IL-6 = Interleukin-6; MADRS = Montgomery–Åsberg Depression Rating Scale; NfL = Neurofilament light chain; Q-LES-Q = Quality of Life Enjoyment and Satisfaction Questionnaire; TAC = Total Antioxidant Capacity; YMRS = Young Mania Rating Scale.




FIGURE 4 | Visualisation of the model space from the BMA analysis of GFAP correlates. BDRS = Bipolar Depression Rating Scale; CGI-S = Clinical Global Impressions—Severity Scale; GFAP = glial fibrillary acidic protein; HAM-A = Hamilton Anxiety Rating Scale; IL-6 = Interleukin-6; MADRS = Montgomery–Åsberg Depression Rating Scale; NfL = Neurofilament light chain; Q-LES-Q = Quality of Life Enjoyment and Satisfaction Questionnaire; TAC = Total Antioxidant Capacity; YMRS = Young Mania Rating Scale.

future research to use a multimodal approach, combining fluid-based biomarker levels with neuroimaging to strengthen the findings.

In conclusion, this is the largest study to date that has investigated plasma NfL and GFAP in people with bipolar disorder. We found that both are mildly elevated compared to healthy controls, with higher NfL associated with a longer duration of bipolar disorder, while GFAP was associated with a later age of onset. Taken together, our study further supports the

neuroprogression hypothesis, as individuals with bipolar disorder had elevated GFAP levels, a neuroinflammatory marker, compared to healthy controls, and those with longer duration of illness exhibited higher neuroaxonal burden outpacing chronological age. Moreover, these biomarkers may be potential candidates to identify different stages and phenotypes of bipolar disorder, such as neuroprogression or later onset of illness. Further studies with longitudinal data are needed to further validate our findings and better understand the neurobiological underpinnings of bipolar disorder.

Author Contributions

Matthew J.Y. Kang: formulating research question, study design, data analysis, manuscript writing and submission. Dhamidhu Eratne: formulating research question, study design, data analysis, manuscript revision and supervision. Charles B. Malpas: formulating research question, study design, data analysis, statistical support and supervision. Alexander F. Santillo: formulating research question, study design, data analysis, statistical support and supervision. Cassandra Wannan: study design, manuscript revision. Claudia Cicognola: study design, manuscript revision. Shorena Janelidze: study design, data analysis, manuscript revision. Olivia Dean: study design, manuscript revision. Oskar Hansson: study design, manuscript revision. Michael Berk: study design, manuscript revision. Adam J. Walker: study design, manuscript revision. Jasleen Grewal: study design, manuscript revision. Dennis Velakoulis: study design, data analysis, manuscript revision and supervision. Philip B. Mitchell: study design, manuscript revision and supervision. Christos Pantelis: study design, manuscript revision and supervision. Malcolm Hopwood: study design, manuscript revision and supervision.

Acknowledgements

The authors would like to thank the participants for their contribution to the study, as well as the broader MiND Study Group and collaborators. Open access publishing facilitated by The University of Melbourne, as part of the Wiley - The University of Melbourne agreement via the Council of Australian University Librarians.

Conflicts of Interest

O.H. has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare, and Roche. In the past two years, he has received consultancy/speaker fees from Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. O.D. has received grant support from the Brain and Behaviour Foundation, Simons Autism Foundation, Stanley Medical Research Institute, Deakin University, Lilly, NHMRC and ASBDD/Servier. She has also received in kind support from BioMedica Nutraceuticals, NutritionCare and Bioceticals. All other authors report no biomedical financial interests or potential conflicts of interest.

Data Availability Statement

Deidentified and pooled data is available on request from the corresponding author.

References

1. M. Berk, "Neuroprogression: Pathways to Progressive Brain Changes in Bipolar Disorder," *International Journal of Neuropsychopharmacology* 12, no. 4 (2009): 441–445.
2. M. Berk, F. Kapczinski, A. C. Andreazza, et al., "Pathways Underlying Neuroprogression in Bipolar Disorder: Focus on Inflammation, Oxidative Stress and Neurotrophic Factors," *Neuroscience and Biobehavioral Reviews* 35, no. 3 (2011): 804–817.
3. J. Velosa, A. Delgado, E. Finger, M. Berk, F. Kapczinski, and T. de Azevedo Cardoso, "Risk of Dementia in Bipolar Disorder and the Interplay of Lithium: A Systematic Review and Meta-Analyses," *Acta Psychiatrica Scandinavica* 141, no. 6 (2020): 510–521.
4. G. Scaini, S. S. Valvassori, A. P. Diaz, et al., "Neurobiology of Bipolar Disorders: A Review of Genetic Components, Signaling Pathways, Biochemical Changes, and Neuroimaging Findings," *Brazilian Journal of Psychiatry* 42, no. 5 (2020): 536–551.

5. L. N. Yatham, A. Schaffer, L. V. Kessing, et al., "Early Intervention, Relapse Prevention, and Neuroprogression in Bipolar Disorder: The Evidence Matters," *Bipolar Disorders* 26, no. 4 (2024): 313–316.
6. S. A. Strojilovich, C. Samamé, and D. Quiroz, "The Neuroprogression Hypothesis in Bipolar Disorders: Time for Apologies?," *Bipolar Disorders* 25, no. 5 (2023): 353–354.
7. E. Vieta, M. Berk, T. G. Schulze, et al., "Bipolar Disorders," *Nature Reviews. Disease Primers* 4, no. 1 (2018): 1–16.
8. B. Arslan and H. Zetterberg, "Neurofilament Light Chain as Neuronal Injury Marker—What Is Needed to Facilitate Implementation in Clinical Laboratory Practice?," *Clinical Chemistry and Laboratory Medicine* 61, no. 7 (2023): 1140–1149.
9. S. Abu-Rumeileh, A. Abdelhak, M. Foschi, et al., "The Multifaceted Role of Neurofilament Light Chain Protein in Non-Primary Neurological Diseases," *Brain* 146 (2022): 421–437.
10. F. Bavato, C. Barro, L. K. Schnider, et al., "Introducing Neurofilament Light Chain Measure in Psychiatry: Current Evidence, Opportunities, and Pitfalls," *Molecular Psychiatry* 29 (2024): 2543–2559.
11. P. Steinacker, M. R. Al Shweiki, P. Oeckl, et al., "Glial Fibrillary Acidic Protein as Blood Biomarker for Differential Diagnosis and Severity of Major Depressive Disorder," *Journal of Psychiatric Research* 144 (2021): 54–58, <https://doi.org/10.1016/j.jpsychires.2021.09.012>.
12. M. Kang, J. Grewal, D. Eratne, et al., "Neurofilament Light and Glial Fibrillary Acidic Protein in Mood and Anxiety Disorders: A Systematic Review and Meta-Analysis," *Brain, Behavior, and Immunity* 123 (2025): 1091–1102.
13. V. Aggio, L. Fabbella, A. Finardi, et al., "Neurofilaments Light: Possible Biomarker of Brain Modifications in Bipolar Disorder," *Journal of Affective Disorders* 300 (2022): 243–248.
14. D. Eratne, M. Kang, C. Malpas, et al., "Plasma Neurofilament Light in Behavioural Variant Frontotemporal Dementia Compared to Mood and Psychotic Disorders," *Australian and New Zealand Journal of Psychiatry* 58 (2023): 70–81.
15. E. von Elm, D. G. Altman, M. Egger, et al., "The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies," *Annals of Internal Medicine* 147, no. 8 (2007): 573–577.
16. M. Berk, A. Turner, G. S. Malhi, et al., "A Randomised Controlled Trial of a Mitochondrial Therapeutic Target for Bipolar Depression: Mitochondrial Agents, N-Acetylcysteine, and Placebo," *BMC Medicine* 17, no. 1 (2019): 18.
17. C. A. Bousman, S. Luza, S. G. Mancuso, et al., "Elevated Ubiquitinated Proteins in Brain and Blood of Individuals With Schizophrenia," *Scientific Reports* 9, no. 1 (2019): 2307.
18. D. Eratne, S. Janelidze, C. B. Malpas, et al., "Plasma Neurofilament Light Chain Protein Is Not Increased in Treatment-Resistant Schizophrenia and First-Degree Relatives," *Australian and New Zealand Journal of Psychiatry* 56, no. 10 (2022): 1295–1305.
19. N. J. Ashton, M. Suárez-Calvet, T. K. Karikari, et al., "Effects of Pre-Analytical Procedures on Blood Biomarkers for Alzheimer's Pathophysiology, Glial Activation, and Neurodegeneration," *Alzheimers Dement (Amst)* 13, no. 1 (2021): e12168.
20. A. Keshavan, A. Heslegrave, H. Zetterberg, and J. M. Schott, "Stability of Blood-Based Biomarkers of Alzheimer's Disease Over Multiple Freeze-Thaw Cycles," *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* 10 (2018): 448–451.
21. P. Altmann, F. Leutmezer, H. Zach, et al., "Serum Neurofilament Light Chain Withstands Delayed Freezing and Repeated Thawing," *Scientific Reports* 10, no. 1 (2020): 19982.

22. R Core Team, *R: A Language and Environment for Statistical Computing* (R Foundation for Statistical Computing, 2021), <https://www.R-project.org/>.
23. The jamovi project, “jamovi (Version 2.6) [Computer Software],” (2025), <https://www.jamovi.org>.
24. M. Gallucci, “GAMLj3: GAMLj Suite for Linear Models. R package version 3.4.2,” (2025).
25. A. E. Raftery, D. Madigan, and J. A. Hoeting, “Bayesian Model Averaging for Linear Regression Models,” *Journal of the American Statistical Association* 92, no. 437 (1997): 179–191.
26. M. A. Clyde, J. Ghosh, and M. L. Littman, “Bayesian Adaptive Sampling for Variable Selection and Model Averaging,” *Journal of Computational and Graphical Statistics* 20, no. 1 (2011): 80–101.
27. X. Zhou, Q. Xiao, L. Xie, F. Yang, L. Wang, and J. Tu, “Astrocyte, a Promising Target for Mood Disorder Interventions,” *Frontiers in Molecular Neuroscience* 12 (2019): 136, <https://doi.org/10.3389/fnmol.2019.00136/full>.
28. A. D. Rivera and A. M. Butt, “Astrocytes Are Direct Cellular Targets of Lithium Treatment: Novel Roles for Lysyl Oxidase and Peroxisome-Proliferator Activated Receptor- γ as Astroglial Targets of Lithium,” *Translational Psychiatry* 9, no. 1 (2019): 1–14.
29. F. Benedetti, V. Aggio, M. Pratesi, G. Greco, and R. Furlan, “Neuroinflammation in Bipolar Depression,” *Frontiers in Psychiatry* 11 (2020): 71.
30. G. S. Malhi, E. Bell, G. Morris, and A. Hamilton, “Staging Bipolar Disorder: An Alluring Proposition,” *Bipolar Disorders* 22, no. 7 (2020): 660–663.
31. N. J. Ashton, S. Janelidze, A. Al Khleifat, et al., “A Multicentre Validation Study of the Diagnostic Value of Plasma Neurofilament Light,” *Nature Communications* 12, no. 1 (2021): 3400.
32. D. Eratne, S. M. Loi, Q. X. Li, et al., “Cerebrospinal Fluid Neurofilament Light Chain Differentiates Primary Psychiatric Disorders From Rapidly Progressive, Alzheimer’s Disease and Frontotemporal Disorders in Clinical Settings,” *Alzheimer’s & Dementia* 18, no. 11 (2022): 2218–2233.
33. N. Koutsouleris, C. Davatzikos, S. Borgwardt, et al., “Accelerated Brain Aging in Schizophrenia and Beyond: A Neuroanatomical Marker of Psychiatric Disorders,” *Schizophrenia Bulletin* 40, no. 5 (2014): 1140–1153.
34. G. R. Fries, M. J. Zamzow, T. Andrews, O. Pink, G. Scaini, and J. Quevedo, “Accelerated Aging in Bipolar Disorder: A Comprehensive Review of Molecular Findings and Their Clinical Implications,” *Neuroscience and Biobehavioral Reviews* 112 (2020): 107–116.
35. J. M. Collins, A. D. Bindoff, E. Roccati, J. E. Alty, J. C. Vickers, and A. E. King, “Does Serum Neurofilament Light Help Predict Accelerated Cognitive Ageing in Unimpaired Older Adults?,” *Frontiers in Neuroscience* 17 (2023): 1237284, <https://doi.org/10.3389/fnins.2023.1237284/full>.
36. M. Khalil, L. Pirpamer, E. Hofer, et al., “Serum Neurofilament Light Levels in Normal Aging and Their Association With Morphologic Brain Changes,” *Nature Communications* 11, no. 1 (2020): 812.
37. J. Simrén, U. Andreasson, J. Gobom, et al., “Establishment of Reference Values for Plasma Neurofilament Light Based on Healthy Individuals Aged 5–90 Years,” *Brain Communications* 4, no. 4 (2022): fcacl74.
38. C. N. Harada, M. C. Natelson Love, and K. Triebel, “Normal Cognitive Aging,” *Clinics in Geriatric Medicine* 29, no. 4 (2013): 737–752.
39. A. Yuan, M. V. Rao, Veeranna, and R. A. Nixon, “Neurofilaments at a Glance,” *Journal of Cell Science* 125, no. 14 (2012): 3257–3263.
40. C. M. J. Wannan, D. Eratne, A. F. Santillo, et al., “Plasma Neurofilament Light Protein Is Differentially Associated With Age in Individuals With Treatment-Resistant Schizophrenia and Bipolar Affective Disorder Compared to Controls,” *Psychiatry Research* 339 (2024): 116073.
41. I. C. Passos, B. Mwangi, E. Vieta, M. Berk, and F. Kapczinski, “Areas of Controversy in Neuroprogression in Bipolar Disorder,” *Acta Psychiatrica Scandinavica* 134, no. 2 (2016): 91–103.
42. B. Wollenhaupt-Aguiar, F. Kapczinski, and B. Pfaffenseller, “Biological Pathways Associated With Neuroprogression in Bipolar Disorder,” *Brain Sciences* 11, no. 2 (2021): 228.
43. Z. Degraff, G. S. Souza, N. A. Santos, et al., “Brain Atrophy and Cognitive Decline in Bipolar Disorder: Influence of Medication Use, Symptomatology and Illness Duration,” *Journal of Psychiatric Research* 163 (2023): 421–429.
44. C. Abé, C. R. K. Ching, B. Liberg, et al., “Longitudinal Structural Brain Changes in Bipolar Disorder: A Multicenter Neuroimaging Study of 1232 Individuals by the ENIGMA Bipolar Disorder Working Group,” *Biological Psychiatry* 91, no. 6 (2022): 582–592.
45. R. Peters, “Ageing and the Brain,” *Postgraduate Medical Journal* 82, no. 964 (2006): 84–88.
46. W. W. Aamodt, T. Waligorska, J. Shen, et al., “Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease,” *Movement Disorders* 36, no. 12 (2021): 2945–2950.
47. A. Gaur, D. Gallagher, N. Herrmann, et al., “Neurofilament Light Chain as a Biomarker of Global Cognition in Individuals With Possible Vascular Mild Cognitive Impairment,” *Journal of Geriatric Psychiatry and Neurology* 38, no. 1 (2025): 62–72.
48. P. M. Lukacs, K. P. Burnham, and D. R. Anderson, “Model Selection Bias and Freedman’s Paradox,” *Annals of the Institute of Statistical Mathematics* 62, no. 1 (2010): 117–125.
49. V. Patel and P. Edison, “Cardiometabolic Risk Factors and Neurodegeneration: A Review of the Mechanisms Underlying Diabetes, Obesity and Hypertension in Alzheimer’s Disease,” *Journal of Neurology, Neurosurgery, and Psychiatry* 95, no. 6 (2024): 581–589.
50. L. G. Sylvania, R. C. Shelton, D. E. Kemp, et al., “Medical Burden in Bipolar Disorder: Findings From the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder Study (Bipolar CHOICE),” *Bipolar Disorders* 17, no. 2 (2015): 212–223.
51. D. Eratne and A. F. Santillo, “A Useful Map With Some Blind Spots Still: Neurofilament Light Protein Differentiating Behavioral Variant Frontotemporal Dementia From Psychiatric Disorders,” *American Journal of Geriatric Psychiatry* 32 (2024): 1002–1003.
52. G. Serafini, M. Pardini, F. Monacelli, et al., “Neuroprogression as an Illness Trajectory in Bipolar Disorder: A Selective Review of the Current Literature,” *Brain Sciences* 11, no. 2 (2021): 276.
53. J. Jakobsson, M. Bjerke, C. J. Ekman, et al., “Elevated Concentrations of Neurofilament Light Chain in the Cerebrospinal Fluid of Bipolar Disorder Patients,” *Neuropsychopharmacology* 39, no. 10 (2014): 2349–2356.
54. F. Bavato, A. K. Kexel, B. Kluwe-Schiavon, et al., “A Longitudinal Investigation of Blood Neurofilament Light Chain Levels in Chronic Cocaine Users,” *Molecular Neurobiology* 60, no. 7 (2023): 3935–3944.
55. M. C. Huang, H. Y. Tu, R. H. Chung, et al., “Changes of Neurofilament Light Chain in Patients With Alcohol Dependence Following Withdrawal and the Genetic Effect From ALDH2 Polymorphism,” *European Archives of Psychiatry and Clinical Neuroscience* 274, no. 2 (2024): 423–432.

Supporting Information

Additional supporting information can be found online in the Supporting Information section.